QUANTA INC. QNTA overview

BURBANK, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today pre-clinical study results showing that the Company’s lead drug candidate Escozine®, when combined with leading chemotherapy agents such as Cyclophosphamide, Etoposide and Cisplatin, has a synergistic...

BURBANK, CA, April 19, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), reported today its financial results from fiscal year 2020 in its annual filing where the Company reported over $1 million in revenue. In addition, the new management team released the following statement regarding the filing:...

BURBANK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that Quanta’s President and Director Philip Sands will be presenting virtually at a cannabis investing conference, the 2021 Sequire Cannabis Conference, on Tuesday, April 20, at 3 p.m. EST/12 p.m. PST....

BURBANK, Calif., April 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it has filed its final set of data requested by the US Food and Drug Administration (FDA) for its Pre-Investigational New Drug (PIND #150335) filing on its lead drug candidate Escozine® as a COVID-19...

BURBANK, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today pre-clinical study results conducted at one of the leading cancer research centers in the United States showing that the Company’s lead drug candidate Escozine® caused up to 95 percent Specific Induced...

BURBANK, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that the Company has received a significant purchase order for its nutraceutical product Immunapen™, a consumer-facing product designed to increase the quality of life of users through enhancing their...

BURBANK, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that Dr. Ramón Feliz MD, PhD, an oncological surgeon practicing medicine in the Dominican Republic, has made an official recommendation for inclusion of Medolife’s drug candidate Escozine® in treatment...

BURBANK, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it has furthered the expansion of its scorpion reservation located in the Dominican Republic (“DR”). The first-of-its-kind location has been expanded by approximately 6,350 square meters where the...

BURBANK, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it has completed production of a batch of its lead drug candidate Escozine® and finalized analysis of the batch, which is now ready for submission to the US Food and Drug Administration (FDA) as a part...

BURBANK, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today clinical trial results conducted on its lead drug candidate Escozine® where the drug eradicated in vitro bladder (SCaBER) and ovarian (OVCAR-3 and IGR-OV1) cancer cell lines when administered for 24 hours....

BURBANK, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today positive results in a safety and toxicity study conducted on its polarized drug candidate derived from a small molecular peptide found in scorpions, designed to treat patients with the SARS-CoV-2 virus, also...

BURBANK, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today preclinical trial results on its lead drug candidate Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment for various indications including the...

BURBANK, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), today announced that the Company has appointed CMW Media , a creative and public relations agency specializing in emerging markets, as its strategic communications firm. In recent months, Medolife has announced a series of significant milestones, including being acquired by Quanta, Inc. which has given Medolife majority control of...

BURBANK, CA / ACCESSWIRE / February 23, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA), announced today that Medolife and CURE Pharmaceutical Holding Corp. ("CURE") signed a Collaboration and Joint Development Agreement on February 7, 2021. Medolife's polarization technology and CURE Pharmaceutical's CUREfilm® technology each had a strong market advantage prior to the multifaceted collaboration. Now, the collaboration of these unique,...

BURBANK, CA / ACCESSWIRE / February 2, 2021 / Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK:QNTA), announced today that it began major distribution of its Quanta Muscle Rub™ products in Canada in collaboration with Better Health Sciences, Inc. During a pilot sale campaign, Better Health Sciences received exceptionally positive feedback from its customers on the Quanta Muscle Rub™, a topical product containing polarized CBD. In the first year, both...